Dr. Winter Discusses Copanlisib in Follicular Lymphoma
Jane N. Winter, MD
Jane N. Winter, MD, professor of medicine, Division of Hematology/Oncology, Northwestern University, discusses copanlisib (Aliqopa) in follicular lymphoma.
The intravenous pan-class I PI3K inhibitor copanlisib has shown predominant activity against the PI3K-alpha and -delta isoforms in follicular lymphoma.
Winter says that the category of PI3K inhibitors continues to grow in this disease, and this class of agents will positively add to the armamentarium.